INTERPACE DIAGNOSTICS GROUP, INC. (NASDAQ:IDXG) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements of Business Acquired
The BioPharma Business audited Special Purpose Combined Statements of Revenues and Direct Expenses for the years ended December 31, 2018 and 2017 as well as the accompanying notes and independent auditors’ report are filed as Exhibit 99.1 and are incorporated by reference herein.
The BioPharma Business Special Purpose Combined Statement of Assets Acquired and Liabilities Assumed as of July 15, 2019, as well as the accompanying notes are filed as Exhibit 99.2 and are incorporated by reference herein.
The BioPharma Business unaudited Special Purpose Interim Combined Statements of Revenues and Direct Expenses for the six months ended June 30, 2019 and 2018, as well as the accompanying notes are filed as Exhibit 99.3 and are incorporated by reference herein.
to a letter dated September 10, 2019 from the staff of the Securities and Exchange Commission’s Division of Corporation Finance, the staff stated that it would not object to the filing of abbreviated financial statements of the BioPharma Business in lieu of the full financial statements required by Rule 8-04 of Regulation S-X.
(b) Pro Forma Financial Information
The Company’s unaudited Pro forma Consolidated Financial Information giving effect to the Acquisition as of and for the six months ended June 30, 2019 and for the year ended December 31, 2018, as well as the accompanying notes are filed as Exhibit 99.4 and are incorporated by reference herein.
(d) Exhibits
| 23.1 | Consent of BDO USA, LLP, Independent Registered Public Accounting Firm |
| 99.1 | Special Purpose Combined Statements of Revenues and Direct Expenses for the years ended December 31, 2018 and 2017 |
| 99.2 | Special Purpose Combined Statement of Assets Acquired and Liabilities Assumed as of July 15, 2019 |
| 99.3 | Special Purpose Interim Combined Statements of Revenues and Direct Expenses for the six months ended June 30, 2019 and 2018 |
| 99.4 | Unaudited Pro forma Consolidated Financial Information as of and for the six months ended June 30, 2019 and for the year ended December 31, 2018 |
Interpace Diagnostics Group, Inc. Exhibit
EX-23.1 2 ex23-1.htm Consent of Independent Registered Public Accounting Firm Interpace Diagnostics Group,…
To view the full exhibit click here
About INTERPACE DIAGNOSTICS GROUP, INC. (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.